Fesofer Capsule
Isoprenaline
Hukam Pharmaceuticals Pvt. Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 4.00 NPR |
Indications
Fesofer Capsule is used for:
Bronchospasm during anaesthesia, Emergency treatment of cardiac arrhythmias, Postoperative cardiac patients with bradycardia, Complete heart block following closure of ventricular septal defects, For temporary use in 3rd degree atrioventricular block until pacemaker insertion
Adult Dose
Intravenous
Bronchospasm during anaesthesia
Adult: 0.01-0.02 mg (0.5-1 ml of a 1:50,000 dilution), repeat when necessary.
Elderly: Lower doses may be required.
Emergency treatment of cardiac arrhythmias
Adult: IV bolus inj: Initially, 0.02-0.06 mg (1-3 ml of a 1:50,000 dilution). Subsequent dose range: 0.01-0.2 mg. IV infusion: Initially, 5 mcg/minute. Adjust subsequent doses based on patient's response; usual range: 2-20 mcg/minute.
Parenteral
Postoperative cardiac patients with bradycardia
Adult: For less urgent situations. Initial: 0.2 mg via IM or SC admin. Subsequent dose ranges: 0.02-1 mg (via IM admin) or 0.15-0.2 mg (via SC admin).
Intravenous
For temporary use in 3rd degree atrioventricular block until pacemaker insertion
Adult: 2-10 mcg/minute via IV infusion. Adjust subsequent rate based on patient's heart rate and rhythm response.
Complete heart block following closure of ventricular septal defects
Adult: 0.04-0.06 mg (2-3 mL of a 1:50,000 dilution) as bolus doses.
Adjunct in shock
Adult: 0.5-5 mcg/minute, adjust subsequent rate based on patient's response. In advanced stages: rates >30 mcg/minute have been used. Not recommended for >1 hr usage in patients with septic shock.
As a diagnostic agent
Adult: For diagnosing etiology of mitral regurgitation: 4 mcg/minute as infusion. For diagnosis of coronary artery disease or lesions: 1-3 mcg/minute as infusion.
Child Dose
Emergency treatment of cardiac arrhythmias
Adult: IV bolus inj: Initially, 0.02-0.06 mg (1-3 ml of a 1:50,000 dilution). Subsequent dose range: 0.01-0.2 mg. IV infusion: Initially, 5 mcg/minute. Adjust subsequent doses based on patient's response; usual range: 2-20 mcg/minute.
Child: Initially, 0.1 mcg/kg/minute. Subsequent dose range: 0.1-1 mcg/kg/minute.
Parenteral
Postoperative cardiac patients with bradycardia
Adult: For less urgent situations. Initial: 0.2 mg via IM or SC admin. Subsequent dose ranges: 0.02-1 mg (via IM admin) or 0.15-0.2 mg (via SC admin).
Child: 0.029 mcg/kg/minute via IV infusion.
Complete heart block following closure of ventricular septal defects
Adult: 0.04-0.06 mg (2-3 mL of a 1:50,000 dilution) as bolus doses.
Child: Infants: 0.01-0.03 mg (0.5-1.5 mL of a 1:50,000 dilution) as bolus dose.
Renal Dose
Administration
Reconstitution: Reconstitute with supplied diluent only.
Contra Indications
Tachyarrhythmias; tachycardia or heart block due to digitalis intoxication; ventricular arrhythmias which require inotropic therapy; angina pectoris.
Precautions
Coronary artery disease, coronary insufficiency, diabetes, hyperthyroidism. Pregnancy and lactation. Parenteral: May paradoxically worsen heart block or precipitate Adams-Stokes attacks during normal sinus rhythm or transient heart block. Doses which can increase heart rate to >130 beats/min may increase the risk of inducing ventricular arrhythmias; caution in patients with failing heart or in those with significant degree of arteriosclerosis.
Monitor response to therapy by frequent determination of the central venous pressure and blood gases. Ensure adequate ventilation. Monitor acid-base balance and correct any electrolyte disturbances. Inhalation: Severe paradoxical airway resistance may occur with repeated and excessive use. Carefully instruct the patient in the proper technique of admin.
Pregnancy-Lactation
Interactions
Additive peripheral vasoconstriction may occur with ergot alkaloids. Cardiac, bronchodilating and vasodilating effects may be antagonised by β-blockers e.g. propranolol.
Potentially Fatal: IV: Severe arrhythmias may occur with epinephrine, digitalis, cyclopropane, halogenated hydrocarbon anaesthetics.
Adverse Effects
Side effects of Isoprenaline :
Nervousness, restlessness, insomnia, anxiety, tension, blurring of vision, fear, excitement. Rarely, sweating, weakness, pallor, dizziness, mild tremor, headache, flushing of the face or skin, nausea, vomiting, tinnitus, lightheadedness, asthenia. Swelling of the parotid glands (prolonged use). Pulmonary oedema, dyspneoa. Palpitation and ventricular tachycardia. Transient myocardial ischaemia or myocardial dysfunction in children.
Potentially Fatal: Ventricular arrhythmias.
Mechanism of Action
Isoprenaline is a sympathomimetic that acts directly on β-adrenergic receptors. It stimulates the CNS, has powerful stimulating action on the heart, and has bronchodilating properties.
Note
Fesofer Capsule manufactured by Hukam Pharmaceuticals Pvt. Ltd.. Its generic name is Isoprenaline. Fesofer is availble in Nepal.
Farmaco Nepal drug index information on Fesofer Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.